Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.

ABSTRACT: WCK 5222 is a novel β-lactam-β-lactam-enhancer combination of cefepime (FEP) and zidebactam (ZID). ZID is a novel β-lactam enhancer with a dual action of binding to Gram-negative penicillin-binding protein 2 (PBP2) and β-lactamase inhibition. WCK 5222 is being developed as a new therapeutic option for the treatment of complicated multidrug-resistant Gram-negative pathogen infections. We investigated the effect of renal impairment on the pharmacokinetics (PK) and safety of WCK 5222 in 48 subjects based on Cockcroft-Gault-estimated creatinine clearance (CL_CR). We enrolled mild (n = 6; CL_CR, 60 to <90 ml/min), moderate (n = 6; CL_CR, 30 to <60 ml/min), and severe (n = 6; CL_CR, <30 ml/min; not on dialysis) impairment, end-stage re

SUBMITTER: Preston RA 

PROVIDER: S-EPMC6325229 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature